Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

Symptom management and combating side effects

David Larkin – ACT Government Health Directorate, Australia

Symptom management and combating side effects ( David Larkin – ACT Government Health Directorate, Australia )

Circulating metastasis-initiating cells in breast cancer

Prof Andreas Trumpp - German Cancer Research Centre (DKFZ), Heidelberg, Germany

Circulating metastasis-initiating cells in breast cancer ( Prof Andreas Trumpp - German Cancer Research Centre (DKFZ), Heidelberg, Germany )

Bevacizumab benefits beyond progression in TML study subgroups

Dr Thierry André – Hôpital Saint Antoine, Paris, France

Bevacizumab benefits beyond progression in TML study subgroups ( Dr Thierry André – Hôpital Saint Antoine, Paris, France )

The immuno side of melanoma

Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

The immuno side of melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Use of mesenchymal stromal cells against graft-versus-host disease

Prof Willem Fibbe – Lieden University Medical Center, Holland

Use of mesenchymal stromal cells against graft-versus-host disease ( Prof Willem Fibbe – Lieden University Medical Center, Holland )

Next generation sequencing and the monoclonal structure of multiple myeloma

Dr Niccolo Bolli – University of Cambridge, UK

Next generation sequencing and the monoclonal structure of multiple myeloma ( Dr Niccolo Bolli – University of Cambridge, UK )

Assessing iron overload and toxicity

Prof John Porter - University College London, UK

Assessing iron overload and toxicity ( Prof John Porter - University College London, UK )

Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy

Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, MA, USA

Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy ( Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, MA, USA )

Drug development in small cell and non-small cell lung cancer

Dr Leora Horn - Vanderbilt-Ingram Cancer Center, Nashville, USA

Drug development in small cell and non-small cell lung cancer ( Dr Leora Horn - Vanderbilt-Ingram Cancer Center, Nashville, USA )

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma

Dr Sagar Lonial – Emory University, Atlanta, USA

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma ( Dr Sagar Lonial – Emory University, Atlanta, USA )

Effects of panitumumab against oesophageal-gastro cancer and carcinomas

Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK

Effects of panitumumab against oesophageal-gastro cancer and carcinomas ( Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK )

Regorafenib effective for GISTs that progress due to resistance to approved...

Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies ( Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer